References
Angell, M. (2004). The truth about the drug companies. New York: Random House.
Arora, A., Ceccagnoli, M., Cohen, W. M. (2003). R&D and the Patent Premium. National Bureau of Economic Research working paper no. 9431.
Cohen, W. M., Nelson, R. R., & Walsh, J. (2000). Protecting their intellectual assets: Appropriability conditions and why US manufacturing firms patent (or not). National Bureau of Economic Research working paper no. 7552.
Mansfield, E. (1986). Patents and innovation: An empirical study. Management Science, 32, 173–181.
Scherer, F. M. (1980). Industrial market structure and economic performance. Chicago: Rand-McNally.
Scherer, F. M. (2002). The economics of human gene patents. Academic Medicine, 77(12), 1348–1367.
Taylor, C. T., & Silberston, Z. A. (1973). The economic impact of the patent system. Cambridge: Cambridge University Press.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scherer, F.M. Michele Boldrin and David K. Levine: Against Intellectual Property. Const Polit Econ 20, 94–97 (2009). https://doi.org/10.1007/s10602-008-9074-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10602-008-9074-0